AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01696097 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DASH diet counseling
Description: Comparison of protein source (chicken and fish vs. pork) as part of DASH diet on blood pressure regulation and blood lipids.
Study NCT03447678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: humanized antibody used in cancer immunotherapy
Study NCT03814239 — intervention group
Intervention type: OTHER
Intervention: protocol
Description: In patients of Group Protocol , basal crystalloid infusion was started at 4 ml/kg/h right after general anesthesia induction and intubation. ClearSight System (Edwards Lifesciences Cop, Irvine, CA, USA) was used to measure stroke volume variation and cardiac output, continuously and noninvasively through finger- cuffed technology. If SVV was >15% rapid crystalloid bolus of 10ml/kg or 4ml/kg colloid bolus were administered until it reached a value of ≤15%. After two consecutive fluid boluses SVV remained >15%, administration of noradrenaline infusion was considered.
Study NCT00716248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bucillamine
Description: bucillamine 100 mg, twice a day
Study NCT00716248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: methotrexate 6 mg or more per week
Study NCT00716248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: methotrexate 6 mg or more per week
Study NCT02562365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide, Cyclophosphamide, Carboplatin
Description: CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5)+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
Study NCT03312517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant 10 mg
Description: Subject will receive suvorexant 10mg
Study NCT03312517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant 20 mg
Description: Subject will receive suvorexant 20mg
Study NCT03312517 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo oral capsule
Description: Subject will receive placebo.
Study NCT02624557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Subjects will receive a single dose of 300 mg alpelisib.
Study NCT03737578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delivery of a connected pedometer / accelerometer
Description: Delivery of a connected pedometer / accelerometer that the patient will be asked to wear at least 7 consecutive days / month.~Quality of life and leg restless syndrome questionnaires (auto questionnaire) completed by the patients every 3 months
Study NCT03737578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivery of a connected pedometer / accelerometer
Description: Delivery of a connected pedometer / accelerometer that the patient will be asked to wear at least 7 consecutive days / month.~Quality of life and leg restless syndrome questionnaires (auto questionnaire) completed by the patients every 3 months
Study NCT01871090 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unpaired remote monitoring transmitter
Description: Unpaired remote monitoring transmitter
Study NCT04507087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Documentary
Description: A 20-minute documentary about the health, environmental, and animal welfare consequences of eating meat and animal products
Study NCT04507087 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: A 20-minute unrelated video (a motivational talk entitled Listening to shame)
Study NCT03346408 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: patient (self-questionnaire) and algologist physician (questionnaire)
Study NCT01516515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: placebo
Study NCT01516515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR-T100 with 2.3% of SM
Description: 2.3% of SM in Solanum undatum plant extract
Study NCT02828072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SKY therapy
Description: slow breathing
Study NCT02828072 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: usual drug therapy
Study NCT03509220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBK-1701TC
Description: The subject will receive PBK-1701TC for colonoscopy.
Study NCT03509220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral preparation
Description: The subject will receive the standard oral preparation for colonoscopy
Study NCT00149318 — intervention group
Intervention type: OTHER
Intervention: Biochemical analyses.
Description: Biochemical analyses.
Study NCT05813808 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultra-low-dose computed tomography
Description: 7 ultra-low-dose computed tomography imaging
Study NCT01198613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Ragweed
Description: Intradermal injection 1 x8 administrations 2 weeks apart
Study NCT03269344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin is an anticonvulsant and has been used to manage neuropathic pain and is FDA-approved for the treatment of post-herpetic neuralgia and partial onset seizures
Study NCT03269344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo
Study NCT00860158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
Study NCT00860158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate (LHRH Analogue)
Description: Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
Study NCT00860158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.
Study NCT00002944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00002944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Description: Given IV
Study NCT00002944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride
Description: Given PO
Study NCT00002944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given PO
Study NCT00002944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given PO and IV
Study NCT02174718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal D Patch
Study NCT02174718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Transdermal D Patch
Study NCT02174718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral vitamin D3
Study NCT01198613 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection, 1x8 administrations 2 weeks apart
Study NCT02174718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo patch
Study NCT02174718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Study NCT02174718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral placebo
Study NCT01613326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 50 μg inhalation capsules once a day, delivered via SDDPI
Study NCT01613326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 μg once a day delivered via HandiHaler® device
Study NCT01613326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tiotropium
Description: Placebo to tiotropium 18 μg o.d. once a day delivered via HandiHaler® device.
Study NCT01613326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to NVA237
Description: Placebo to NVA237 50 μg once a day delivered via SDDPI
Study NCT01613326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol/albuterol
Description: salbutamol/albuterol given as a rescue medication via inhaler when needed
Study NCT03479632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic walking program
Description: Participants will make 24 visits over an 8 week period, having 3 sessions per week. Each session will last about one hour.
Study NCT03479632 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: Participants will receive standard care they normally would after a stroke.
Study NCT03980938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neflamapimod
Description: 40 mg neflamapimod capsule
Study NCT03980938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: neflamapimod
Description: 40 mg neflamapimod capsule
Study NCT03980938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo capsule
Study NCT03980938 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule
Study NCT02750358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT02750358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment
Study NCT03798886 — intervention group
Intervention type: OTHER
Intervention: natural cycle
Description: When follicle is ready for ovulation, we will use this injection by intra-dermal route
Study NCT02150538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy pacemaker
Description: biventricular stimulation with cardiac resynchronization therapy pacemaker (crt-p)
Study NCT02150538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual chamber pacemaker
Description: right ventricular stimulation with dual chamber pacemaker
Study NCT01758536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huatuo Zaizao Pills
Description: A tens of herbs botanical drug product 12 gram (g) in 72 mini pills formulation. It is to be used as 12 g each time, twice daily.
Study NCT03798886 — intervention group
Intervention type: OTHER
Intervention: modified natural cycle
Description: we will use that drug in the natural modified transfer group after embryo transfer
Study NCT03798886 — intervention group
Intervention type: OTHER
Intervention: embryo transfer
Description: we will do transfer when the endometrium is ready
Study NCT02118792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Topical Ointment, 2%
Study NCT02118792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching vehicle control
Study NCT01113203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Progressive high intensity resistance training performed twice a week for 16 weeks, and achieving in 7 exercises for the main muscles, the protocol of 4 sets of 6RM and 2 of 4RM.
Study NCT02908880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MANTA vascular closure device
Description: The appropriate size of MANTA closure device will be selected and used for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.
Study NCT01681329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Cognitive-behavioral therapy addressing intolerance of uncertainty, positive beliefs about worry, negative problem orientation, and cognitive avoidance
Study NCT01681329 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: Cognitive-behavioral therapy addressing intolerance of uncertainty, positive beliefs about worry, negative problem orientation, and cognitive avoidance
Study NCT01681329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interpretation training
Description: Computerized interpretation training using Word-Sentence Association Paradigm
Study NCT03799900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: During the Treatment Phase in Part 2, participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
Study NCT03799900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
Study NCT03799900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
Study NCT03799900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
Study NCT01758536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Huatuo Zaizao Pills
Description: A tens of herbs botanical drug product 12 gram (g) in 72 mini pills formulation. It is to be used as 12 g each time, twice daily.
Study NCT02657135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive/Neuropsychological Testing
Description: These tests will be used to determine how the participant will continue with future procedures, and depending on results, may involve the participant returning to complete subsequent testing.
Study NCT02657135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular/Ocular-Motor Testing
Description: These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI and will include dizziness, balance, ocular-motor coordination, and reflexes.
Study NCT02657135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical (Neck) Evaluation
Description: These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI including neck mobility and pain levels.
Study NCT02657135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Evaluation
Description: These evaluations will focus on assessing insomnia (duration, frequency, daytime consequences), combat exposure, and the presence and severity of trauma history.
Study NCT02657135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HDFT MRI
Description: This MRI aims at providing qualitative and quantitative assessments of the nature, location, and extent of white matter injury.
Study NCT02657135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR Spectroscopy (MRS)
Description: This is a noninvasive diagnostic test for measuring biochemical changes in the brain.
Study NCT02657135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEG (Magnetoencephalography)
Description: This is a non-invasive neurophysiological technique that measures the magnetic fields generated by neuronal activity of the brain.
Study NCT03931278 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: learning and recall of a sequence of body movements
Description: The objective of this study to investigate, if learning and recall of a sequence of body movements (steps that realize a pattern on the ground) can be improved by self-produced music (having particular melodic-structures in relation to the pattern), compared to the same sound (a single tone) for each pattern in persons
Study NCT03335085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT03335085 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00662844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D3
Description: Oral, one capsule daily of vitamin D3 (400IU, 800IU, 1600 IU, or 2400IU) plus calcium citrate (1-4 tablets) twice daily to reach a total calcium intake of 1000-1200 mg/day
Study NCT03630770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium-Chain Triglyceride (MCT) Oil
Description: Infants receive 0.5 ml/oz of MCT oil to their prescribed feedings for 21 days or until hospital discharge.
Study NCT01809587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQP-PO-101
Study NCT00250510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated insurance reimbursement
Description: Participants were told they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if they: 1) paid the fee in advance or committed 3 monthly payments in advance, 2) attended 10 of 12 class sessions, and 3) lost at least 6% of their current body weight during the program.
Study NCT03380910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacy and Behavioral Health Team
Description: An interdisciplinary approach using medications through pharmacy support and counseling through behavioral health team members will be used to improve smoking cessation rates.
Study NCT03380910 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational Interviewing
Description: Patients not ready to quit will be offered motivational interviewing to increase readiness to quit.
Study NCT02350803 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mini plate
Description: in the intervention group, 4 L shaped titanium mini plates with 16 screws were fixed immediately after distraction phase and removal of distraction ossteogenesis to prevent the relapse after distraction
Study NCT03204123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ga-HBED-iPSMA PET
Description: Patients will be injected with 100-300 MBq of 68Ga-HBED-iPSMA and after a waiting of 60-90 minutes patients will be scanned from mid-skull to mid-thigh.
Study NCT03204123 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT
Description: PET/CT will be acquired using a GE 710 or 690 time-of-flight PET/CT scanner. Following a waiting period of 60-90 minutes post 68Ga-HBED-iPSMA administration, patients will be scanned from top of the skull to mid-thigh. Images will be acquired with patients in a supine position with their arms raised above their head. If patients cannot raise their arms above the head, the arms will be comfortably positioned and secured by the side of the patient. The PET may be combined with a CT scan as a PET/CT or a MRI scan as PET/MR.
Study NCT03204123 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Patients may undergo a diagnostic MRI of the prostate, other body parts or a whole-body MRI at the same imaging session as clinically indicated.
Study NCT04010669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Description: 2 amp of somatostatin at 1000ml normal saline solution in continuous 24-hour infusion for 5 days
Study NCT04010669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 hours infusion of 1000ml Normal Saline solution 0.9%
Study NCT00167635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral
Description: Cognitive-behavioral over 9 weeks
Study NCT00167635 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: cognitive-behavioral
Description: Cognitive-behavioral over 9 weeks
Study NCT03196128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital communication
Description: Communicating with patients via email and text message.
Study NCT04207541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational interview
Description: Client (who has suboptimal diabetic control with oral anti-diabetic agent) will be advised for insulin initiation with brief motivational interviewing in one session of individual education.
Study NCT01361204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Theanine
Description: Taking 4 tablets of theanine two times daily for 16 days
Study NCT00783484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03716539
Description: PF-03716539 10 mg oral solution, single dose
Study NCT00783484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03716539
Description: PF-03716539 25 mg oral solution, single dose
Study NCT03196128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non digital
Description: Communicating with patients via telephone and written appointment letters.
Study NCT00783484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03716539
Description: PF-03716539 3 mg oral solution, single dose
Study NCT00783484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for 3 mg, 10 mg and 25 mg of PF-03716539 (single dose)
Study NCT01815073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine